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Abstract
Background: To evaluate the sensitivity, specificity and predictive values of spirometry for the
diagnosis of chronic obstructive pulmonary disease (COPD) and asthma in patients suspected of
suffering from an obstructive airway disease (OAD) in primary care.
Methods: Cross sectional diagnostic study of 219 adult patients attending 10 general practices for
the first time with complaints suspicious for OAD. All patients underwent spirometry and
structured medical histories were documented. All patients received whole-body plethysmography
(WBP) in a lung function laboratory. The reference standard was the Tiffeneau ratio (FEV1/VC)
received by the spirometric maneuver during examination with WBP. In the event of inconclusive
results, bronchial provocation was performed to determine bronchial hyper-responsiveness (BHR).
Asthma was defined as a PC20 fall after inhaling methacholine concentration ≤ 16 mg/ml.
Results: 90 (41.1%) patients suffered from asthma, 50 (22.8%) suffered from COPD, 79 (36.1%)
had no OAD. The sensitivity for diagnosing airway obstruction in COPD was 92% (95%CI 80–97);
specificity was 84% (95%CI 77–89). The positive predictive value (PPV) was 63% (95%CI 51–73);
negative predictive value (NPV) was 97% (95%CI 93–99). The sensitivity for diagnosing airway
obstruction in asthma was 29% (95%CI 21–39); specificity was 90% (95%CI 81–95). PPV was 77%
(95%CI 60–88); NPV was 53% (95%CI 45–61).
Conclusion: COPD can be estimated with high diagnostic accuracy using spirometry. It is also
possible to rule in asthma with spirometry. However, asthma can not be ruled out only using
spirometry. This diagnostic uncertainty leads to an overestimation of asthma presence. Patients
with inconclusive spirometric results should be referred for nitric oxide (NO) – measurement and/
or bronchial provocation if possible to guarantee accurate diagnosis.
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Background
Asthma is a common chronic disease with a high preva-
lence of approx. 5% in industrialized nations. It is charac-
terized by a chronic inflammation process which induces
bronchial hyper-responsiveness and in most cases, revers-
ible airway obstruction [1]. Another common pulmonary
disease is chronic obstructive pulmonary disease (COPD)
which shows irreversible airway obstruction, and which is
mostly caused by inhaling tobacco smoke [2]. The preva-
lence of COPD is estimated to be around 10% and
expected to be the fourth most important cause of death
in 2020 [3]. Due to this high morbidity, general practi-
tioners play a key role in detecting the disease as they see
patients during the earlier stages of disease. Spirometric
investigation is seen as a gold standard for diagnosing air-
way obstruction. Therefore, office spirometry is increas-
ingly seen as a quality standard in general practice [4,5].
The efficacy of spirometry in diagnosing COPD was dem-
onstrated by a specialist team, which received referrals for
performing spirometry and bronchodilator reversibility
testing in patients suspected of having COPD [6]. The
DIDASCO Study revealed the difficulty of diagnosing
COPD with screening questionnaires only and concluded
that spirometry is essential for early diagnosis [7]. These
investigations focused on COPD only, which is marked by
irreversible airway obstruction. The diagnostic value of
spirometry for diagnosing asthma marked by reversible
airway obstruction remains unclear. This is of importance,
as asthma needs to be diagnosed by bronchial provoca-
tion testing when spirometry shows no airway obstruction
[8]. One diagnostic study in primary care used spirometry
and bronchial provocation testing for identifying patients
with asthma and COPD [9]. However, this was only car-
ried out in patients complaining of suffering from a
cough; and spirometry was performed by a single special-
ist. Spirometry and bronchial provocation testing were
also used in the DIMCA study [10]. Indeed this was a
screening study performed in a specialist center to detect
patients in early stadiums of asthma or COPD.
Due to the design of these asthma and COPD trials, there
is no evidence of the diagnostic accuracy of spirometry
itself. Therefore, the true degree of the associated diagnos-
tic uncertainty for patients with complaints suspected of
having an airway obstruction remains unclear. The need
for closing this gap of knowledge has been pointed out
several times [11,12]. The difficulty is that the pretest
probability of a disease and its severity in primary care is
lower when compared to a hospital setting, thus hamper-
ing the predictive values of diagnostic tests [13,14]. There-
fore, test results evaluated in hospital settings can not
easily be transferred into general practice [15]. The aim of
this study was to investigate the sensitivity, specificity and
predictive values of spirometry for diagnosing airway
obstruction in asthma and COPD in general practice.
Methods
Design and sample
This cross-sectional study was performed between January
2006 and December 2007 with fourteen general practi-
tioners (GPs) working in ten general practices. 219
patients visiting their GP for the first time with complaints
suggestive of obstructive airway disease (OAD) were con-
secutively included in each practice. Patients visited their
GPs with symptoms such as dyspnea, coughing or expec-
toration. Their medical history was taken with a structured
questionnaire. The patients had not been diagnosed pre-
viously for OAD and they had not received any previous
anti-obstructive medicine. Other exclusion criteria related
to well known contra-indications for bronchodilator
reversibility testing or bronchial provocation, namely
untreated hyperthyreosis, unstable coronary artery dis-
ease, and cardiac arrhythmia. Pregnancy also led to exclu-
sion. The study was approved by the Medical Ethics
Committee of the University of Heidelberg. Patients gave
written informed consent.
On the basis of the pilot study [16] we estimated the pre-
test probability of asthma as being 45% and of COPD as
16%. We estimated the sensitivity for diagnosing asthma
to be 30% and the specificity to be 90%. The sensitivity
and specificity for finding COPD was each estimated to be
90%. Power calculations showed that we had to include at
least 208 patients to determine the sensitivities and specif-
icities with a 95% confidence interval of ± 10% [17]. The
diagnostic values of spirometry in general practice were
calculated separately for each asthma and COPD group to
avoid confusion. The diagnostic value for diagnosing
asthma under optimal conditions was investigated by
pooling all patients and determining the sensitivity, spe-
cificity and predictive values of spirometric maneuvers of
the lung function laboratory.
Index test: Spirometry in general practice
Ten general practices were equipped with the same elec-
tronic spirometer (Medikro SpiroStar USB®) and associ-
ated spirometry software. The spirometer was a hand-held
instrument for lung function testing that has to be con-
nected via USB device to a computer. Spirometric data,
flow-volume and volume-time graphs are displayed in
real-time on the personal computer as the patient per-
forms the spirometry test. A calibration file saves the cali-
bration data for internal quality assurance. Instrument
performance is regularly monitored and performance
deviations are identified by the software. The software
also compares the measured values with reference tables.
The best of three consecutive spirometry recordings was
used in accordance with the guidelines of the EuropeanBMC Pulmonary Medicine 2009, 9:31 http://www.biomedcentral.com/1471-2466/9/31
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Respiratory Society [18]. The maximal inspiratory and
expiratory flow volume curves were generated by forced
deep inspiration and expiration with short intervening
periods of tidal breathing; patients used a nose clip. The
maneuver was performed in a sitting position. Patients
with a FEV1 (forced expiratory volume in one second) <
80% of predicted received a bronchodilation test with an
additional performance of spirometry 20 minutes after
inhaling salbutamol. Obstructive airway disease was diag-
nosed if FEV1/VC  ≤ 70% and/or FEV1  < 80% [4,5].
Obstruction was considered to be reversible on salbuta-
mol (which indicates a diagnosis of asthma) if the bron-
chodilation response Δ FEV1 was ≥12% of the baseline
and ≥200 ml [4] and norm values were reached. GPs were
asked to make their diagnoses based on the test results.
All of the GPs were appropriately trained in the key
aspects of the diagnosis and management of asthma and
COPD, as well as in performing and interpreting spirom-
etry during two educational meetings. The practice assist-
ants completed an intensive 6-hour course and were
trained in performing and interpreting spirometry. Two
outreach visits were also performed with repeated individ-
ual education at a direct, practical level, until the optimal
performance of the spirometry was secured.
Reference test: Bodyplethysmography and bronchial 
provocation
After diagnosis by their GP, all patients were referred to
the lung function laboratory of the University Medical
Hospital at once for investigation with whole-body
plethysmography (WBP). If therapy was necessary due to
asthma or COPD, it was initiated by the GP. However,
patients were instructed not to use any bronchodilator or
inhaled steroid twelve hours before visiting the lung func-
tion laboratory. Spirometry is normally the routine
method for measuring the lung volume required to diag-
nose airflow obstruction – i.e. (forced) vital capacity
((F)VC) or FEV1. However, spirometry is not capable of
providing information about intrathoracic residual vol-
ume or total airway resistance. A WBP is required to meas-
ure residual volume (RV), functional residual capacity
(FRC), and total lung capacity (TLC). Therefore, the
advantage of WBP over spirometry is that it is able to dis-
tinguish between restrictive and obstructive processes.
Additionally, the resistance to airflow can be evaluated
and the response of airway resistance, airway conductance
and thoracic gas volume can be determined in response to
bronchodilator reversibility testing and bronchial provo-
cation. In particular circumstances, measurement of these
lung volumes are strictly necessary for a correct physiolog-
ical diagnosis [19,20]. However, as WBP is only common
in highly developed health care systems and the added
value on top of spirometry remains unclear, it is only rec-
ommended in a few guidelines [21-23].
Measurement technique of whole-body plethysmography and 
bronchial provocation
During WBP, the patient sits inside an airtight chamber
and makes respiratory efforts against the closed shutter,
causing chest volume to expand and decompressing the
air in the lungs. The increase in chest volume reduces the
box's volume, thus increasing the pressure in the box. The
procedures were performed according to standard proto-
cols [21]. Lung function reference values that had been
adjusted for sex, age, and height were used [24]. Patients
with FEV1 < 80% of predicted received a bronchodilation
test with an additional performance of WBP 20 minutes
after inhaling salbutamol. An obstructive airway disease
was diagnosed if FEV1 < 80% and/or FEV1/VC ≤ 0.70. The
obstruction was classified as reversible on a salbutamol
(indicating asthma) when Δ FEV1 was ≥12% and ≥200 ml
from the baseline value [4] and norm values were reached.
In all other cases, the obstruction was classified as not
reversible (Figure 1). If there was no bronchial obstruc-
tion, bronchial provocation was performed to determine
bronchial hyper-responsiveness (BHR). Bronchial provo-
cation is considered to be the best method for diagnosing
asthma [25], although there is conflicting evidence [26],
probably arising from variations in the population stud-
ied, as the diagnostic value increases with pre-test proba-
bility of the disease [27]. Trained lung function
technicians measured bronchial hyper-responsiveness to
methacholine according to the ATS guideline [8]. A diag-
nosis of 'asthma' was made if there was a 20% fall in FEV1
(PC20) from the baseline value after inhaling metha-
choline stepwise until the maximum concentration (16
mg/ml). The pneumologist was blinded against the diag-
nosis of the GP.
Data analysis
The baseline data were presented descriptively. The sensi-
tivity, specificity, and predictive values of the spirometric
investigation (FEV1 and/or FEV1/VC) in general practice
were calculated with two-by-two contingency tables with
the diagnosis of the pneumologist (WBP and bronchial
provocation) as 'gold standard'. The data were analyzed
with SPSS 15.0 for Windows. 95% confidence intervals
were calculated using Wilson's method [28] with the sta-
tistical package CIA (Confidence Interval Analysis) [29].
An explanation of how to interpret PPV and NPV is pro-
vided in figure 2.
Results
Study population
A total of 293 patients were assessed for eligibility (Figure
3). 74 patients received spirometry but did not want to
receive whole body plethysmography and eventually
bronchial provocation. Therefore, altogether 219 patients
participated in the study (127 [57.7%] were female)
(Table 1). The average age was 43.8 years. The averageBMC Pulmonary Medicine 2009, 9:31 http://www.biomedcentral.com/1471-2466/9/31
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body mass index (BMI) was 25.3 (SD 4.4). Of the partici-
pating patients, 78 (35.6%) showed airway obstruction in
general practice and 138 (63.0%) no abnormal findings
in spirometry (Figure 3). Three spirometric results were
lost to follow-up. According to the diagnostic decision
making in the lung function laboratory, 90 (41.1%)
patients had asthma, 50 (22.8%) of the participating
patients had irreversible airway obstruction (COPD), and
79 (36.1%) showed no abnormal findings. A diagnosis of
asthma was made in 76 of the cases with bronchial prov-
ocation, with only 14 patients identified solely on the
basis of bronchodilator reversibility testing. The decision
that the bronchial provocation was positive was made in
74 cases by 20% fall of FEV1 and in two cases by extreme
increase of airway resistance accompanied by develop-
ment of clinical symptoms of asthma during bronchial
provocation. There were no significant differences in sex
(p = 0.719) or obesity (BMI ≥ 30) (p = 0.272) between the
diagnoses (chi-square test).
Performance of spirometry in general practice
Spirometry was performed with full adherence to ERS
guidelines in 86 (39.8%) cases (Table 2). There was mod-
erate adherence to ERS in 82 (38.0%) cases. In 48 (22.2%)
cases the ERS criteria were not fulfilled. E.g., the flow-vol-
ume curves were deformed or not exactly reproduced.
Altogether, 78 (36.1%) spirometric maneuvers showed
airway obstruction. However, a bronchial reversibility test
was only performed in 37 (47.4%) of these 78 cases.
Estimates of diagnostic accuracy of spirometry in general 
practice
In relation to the COPD diagnosis, 26 patients were diag-
nosed false positive (Table 3). 12 of these spirometric
maneuvers showed full/moderate adherence, and 14 were
not according to guidelines. Four patients were diagnosed
as false negative as the forced maneuvers in spirometry
were performed weakly, thus resulting in a virtually nor-
mal Tiffeneau ratio. In these cases was FEV1 > 80% of pre-
dicted and FEV1/VC < 0.70 in the WBP as reference
standard. Sensitivity was 92% and specificity 84%. Thus
the pretest probability could be enhanced reasonably
from 23% to a posttest probability (PPV) of 63%; and
COPD could be ruled out with high certainty (NPV 97%).
63 patients with asthma were diagnosed false negative as
they showed no abnormal findings in spirometry (Table
4). It was only possible to identify them through bron-
chial provocation. Eight patients were diagnosed false
positive; two of these spirometric maneuvers showed
good adherence, and six were not according to guidelines.
The pretest probability was enhanced from 41% up to
77%. However, asthma could not be ruled out, since NPV
(53%) was similar to the pretest probability of 'not having
asthma' (1-p = 59%); and 1-p was within the confidence
interval of NPV (95%CI 45–61). The spirometric results as
a part of the WBP investigation in the lung function labo-
ratory are given in Table 5. Only 14 patients were identi-
fied by airway obstruction FEV1 < 80% of predicted and
Diagnostic decision making with the reference standard (whole-body plethysmography and bronchial provocation) in the lung  function laboratory (COPD = Chronic obstructive pulmonary disease; OAD = obstructive airway disease) Figure 1
Diagnostic decision making with the reference standard (whole-body plethysmography and bronchial provoca-
tion) in the lung function laboratory (COPD = Chronic obstructive pulmonary disease; OAD = obstructive air-
way disease).
Patient with
symptoms
Whole-body plethysmography:
FEV1/VC < 0.70 and/or FEV1< 80%
Yes No
Bronchodilator reversibility testing
Δ FEV1 < 12%
COPD
Δ FEV1 > 12%
and > 200ml
Asthma
Bronchial provocation
with methacholine:
causing fall of Δ FEV1 > 20%
Yes No
No OADBMC Pulmonary Medicine 2009, 9:31 http://www.biomedcentral.com/1471-2466/9/31
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positive bronchial reversibility testing. In addition to this,
under these optimal conditions with optimal differentia-
tion between asthma and COPD, the sensitivity for diag-
nosing asthma solely on basis of spirometric maneuvers
was only 16%. Again, NPV was similar to the pretest prob-
ability of 'not having asthma'.
Diagnostic decision making by the GPs
The comparison of the diagnoses by the general practi-
tioners with the diagnoses of the pneumologists demon-
strated a reasonable agreement with respect to COPD
(Table 6). Additionally, the GPs suspected asthma cor-
rectly in 76.7% of asthma cases despite the diagnostic
uncertainty using spirometry. Indeed the prevalence of
asthma was overestimated with 58.2% of healthy subjects
suspected of having asthma; and 7.8% of patients with
asthma were considered to be healthy.
Discussion
To our knowledge, this is the first study evaluating the
diagnostic accuracy of spirometry for diagnosing airflow
obstruction in patients with asthma or COPD in primary
care. We found that the use of spirometry is feasible
within general practice after training GPs and practice
nurses. Under these conditions, the presence or absence of
COPD can be estimated with a comparatively high diag-
nostic accuracy. It is also possible to rule in asthma. How-
ever, it was impossible to rule out asthma as the sensitivity
was too low.
The prevalence of COPD is increasing in nearly all coun-
tries of the world and a high diagnostic accuracy is a pre-
requisite of optimal therapeutic management. The
important role of spirometry for diagnosing airway
obstruction has already been demonstrated [6,7,30,31].
However, the diagnostic accuracy of spirometry for diag-
Calculation example for the relation between pretest probability, sensitivitiy, specificity, positive predictive value (PPV) and  negative predictive value (NPV) Figure 2
Calculation example for the relation between pretest probability, sensitivitiy, specificity, positive predictive 
value (PPV) and negative predictive value (NPV).
Pretest probability of having the disease (p): is the prevalence of disease in the investigated population
Pretest probability of not having the disease (1-p): is the prevalence of healthy subjects in the investigated population
Sensitivity (sens): is the proportion of people with disease who have a positive test
Specificity (spec): is the proportion of people free of a disease who have a negative test
Positive predictive value (PPV): probability that a patient with a positive test has got really the disease
Negative predictive value (NPV): probability that a patient with a negative test is really healthy
This example illustrates, that a test is useful when the pretest probability is increased up to a reasonable PPV (rule in the disease) or
when NPV is increased reasonably (rule out). The figures illustrate that specificity is more important to rule in (spin = specificity rule in);
and that sensitivity is more important to rule out (snout = sensitivity rule out). The relation between p, sens, spez, PPV and NPV is
described by the Bayes´ Theorem. Indeed a test is only useful, if the pretest probability (p) is out of the range of 95%CI of PPV (in this
example 95%CI =  80%-94%); and/or if the pretest probability of not having the disease (1-p) is out of the range of the 95%CI of NPV 
(in this example 95% CI = 72%-83%). The 95%CI is calculated using Wilson´s method.28 
In this example p is increased up to a meaningful PPV. NPV seems not to be increased reasonably if compared with 1-p.
      
   Disease No  Disease   
positive Right positive 
a = 72 
False positive 
b = 9 
81  Test 
negative False negative 
c = 48 
Right negative 
d = 171 
219 
  Total  120 180  300 
 
Pretest probability (p) Pretest probability (p)
=  d/c+d = 78% NPV
=  a/a+b = 89% PPV
=  d/b+d = 95% spec
=  a/a+c = 60% sens
=  b+d/a+b+c+d = 60% 1-p
=  a+c/a+b+c+d = 40% pBMC Pulmonary Medicine 2009, 9:31 http://www.biomedcentral.com/1471-2466/9/31
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Flow chart of inclusion and diagnostic work up (COPD = Chronic obstructive pulmonary disease; OAD = obstructive airway  disease; OAD = obstructive airway disease) Figure 3
Flow chart of inclusion and diagnostic work up (COPD = Chronic obstructive pulmonary disease; OAD = 
obstructive airway disease; OAD = obstructive airway disease).
Spirometry showing
obstruction
n=80
Spirometry showing
no obstruction
n=139
Patients
receiving spirometry
n=219
Bodyplethysmography /
Bronchoprovocation
n=139
COPD
n=4
Bodyplethysmography / 
Bronchoprovocation
n=80
COPD
n=46
asthma
n=26
no OAD
n=8
asthma
n=64
no OAD
n=71
spirometry results lost
n=2
suspected having COPD
refused to participate
n=39
Patients with symptoms
assessed for egilibility
n=293
suspected having asthma
refused to participate
n=35
spirometry result lost
n=1
Table 1: Characteristics of the study population. Values are number (proportion) or mean (SD); OAD = obstructive airway disease; 
COPD = Chronic obstructive airway disease (n = 219)
Overall
n (%)
Asthma
n (%)
COPD
n (%)
No OAD
n (%)
n 219 (100) 90 (100) 50 (100) 79 (100)
Female 127 (57.7) 55 (61.1) 26 (54.1) 46 (58.2)
Obesity 30 (13.7) 8 (8.9) 10 (20.0) 12 (15.2)
Age (mean in years [sd]) 43.8 [15.6] 37.9 [14.4] 56.9 [11.5] 42.1 [14.4]
Do you sometimes suffer from shortness of breath? (yes) 135 (61.4) 55 (61.1) 39 (76.3) 41 (51.9)
Have you suffered from wheezing in your chest? (yes) 108 (49.1) 47 (52.2) 30 (63.2) 30 (38.0)
Do you often suffer from a cough? (yes) 126 (57.3) 39 (43.3) 32 (65.8) 55 (69.6)
Do you often suffer from expectoration? (yes) 74 (33.6) 22 (24.4) 20 (36.8) 32 (40.5)
Have you been woken up with a feeling of tightness in your chest? (yes) 49 (22.3) 27 (30.0) 9 (10.5) 13 (16.5)
Have you been woken up by an attack of shortness of breath? (yes) 48 (21.8) 24 (26.7) 10 (18.4) 14 (17.7)
Have you suffered an asthma attack? (yes) 14 (6.4) 11 (12.2) 2 (2.6) 1 (1.3)
Do you suffer from any nasal allergies? (yes) 92 (41.8) 44 (48.9) 14 (31.6) 34 (43.0)
Do you often suffer from a common cold? (yes) 73 (33.2) 18 (20.0) 18 (26.3) 37 (46.8)
Do you smoke or did you smoke? (yes) 118 (53.4) 35 (38.9) 43 (86.8) 39 (49.4)
How much do/did you smoke? (mean in pack year [SD]) 11.6 [17.7] 6.6 [12.9] 28.8 [21.7] 6.4 [11.9]BMC Pulmonary Medicine 2009, 9:31 http://www.biomedcentral.com/1471-2466/9/31
Page 7 of 10
(page number not for citation purposes)
nosing COPD has been unknown up to now, thus leading
to diagnostic uncertainty in suspected cases of COPD. Our
results demonstrate that the pretest-probability of 22% of
patients presenting themselves with complaints sugges-
tive of airway obstruction can be increased up to a post-
test probability of 63% for having COPD. This compara-
tively low PPV might be surprising, as the sensitivity was
84% and specificity was 92%. However, this is explainable
by the low pretest probability. Another reason might be
due to sub-maximal maneuvers, leading to false positive
results by underestimation of FEV1  [11]. As a conse-
quence, more efforts in terms of continuous education
would be necessary for an improvement of performance
and an interpretation of spirometry. Nevertheless, COPD
can be definitively excluded (NPV 97%) when spirometry
is performed optimally. For these reasons, spirometry
should be used regularly for diagnosing and managing
COPD in primary care.
In contrast to these promising results is the limited value
of spirometry in excluding asthma. This might be
explained by the reversibility of airway obstruction in
asthma. It proved possible to speculate that patients with
mild or moderate asthma show no airway obstruction
when spirometry is performed. In these cases, it was nec-
essary for the GP to estimate the presence or absence of
asthma on the basis of the patient history and inconclu-
sive spirometry. This was misleading in 53 (24.2%) of
cases (46 patients false positive and 7 patients false nega-
tive). Therefore, alternative methods need to be found for
diagnosing asthma in primary care. Guidelines recom-
mend using the measurement of peak-flow-variability to
diagnose asthma in case of inconclusive spirometry. How-
ever, the low diagnostic value of peak-flow-variability in
primary care has already been demonstrated [32]. The
SAPALDIA study, which used an epidemiologic approach,
has also shown a poor diagnostic value [33]. The measure-
ment of exhaled nitric oxide (NO) which is elevated in
eosinophilic airway inflammation [34] has been shown to
be more promising [35], although the technology is
expensive. Therefore, patients suspected of having asthma
might be tested with NO measurement or should be
referred for bronchial provocation if possible to guarantee
Table 4: 2 × 2 table of spirometry for diagnosing airway 
obstruction in patients with asthma in general practice (n = 168; 
patients with COPD excluded)
asthma no asthma
Spirometry + 26 8
Spirometry - 63 71
168
Pretest probability of having asthma 41%
Pretest probability of not having asthma 59%
Sensitivity 29% (95%CI 21–39)
Specificity 90% (95%CI 81–95)
PPV 77% (95%CI 60–88)
NPV 53% (95%CI 45–61)
Table 2: Performance of spirometry in general practice (n = 216)
Interpretation of flow-volume curve n (%) Bronchodilation test n (%)
Full adherence to ERS 86 (39.8) Was not necessary 138 (36.1)
Adherence to ERS but only two flow-volume curves 69 (31.9) Was necessary and performed 37 (17.1)
No adherence to ERS but first flow-volume curve perfect and showing no pathological 
signs
13 (6.0) Was necessary but not performed 41 (19.0)
No adherence to ERS showing no obstruction 15 (6.9)
No adherence to ERS indicating airway obstruction 33 (15.2)
Table 3: 2 × 2 table of spirometry for diagnosing airway 
obstruction in patients with COPD (n = 208; asthma patients 
with FEV1 <80% of predicted in general practice and in lung 
function laboratory excluded)
COPD No COPD
Spirometry + 44 26
Spirometry - 4 134
208
Pretest probability of having COPD 23%
Pretest probability of not having COPD 77%
Sensitivity 92% (95%CI 80–97)
Specificity 84% (95%CI 77–89)
PPV 63% (95%CI 51–73)
NPV 97% (95%CI 93–99)
Table 5: 2 × 2 table of spirometry for diagnosing airway 
obstruction in patients with asthma in lung function laboratory 
(all patients included with differentiation between asthma and 
COPD)
asthma no asthma
Spirometry + 14 0
Spirometry - 76 129
219
Pretest probability of having asthma 41%
Pretest probability of not having asthma 59%
Sensitivity 16% (95%CI 10–24)
Specificity 100% (95%CI 97–100)
PPV 100% (95%CI 79–100)
NPV 63% (95%CI 56–69)BMC Pulmonary Medicine 2009, 9:31 http://www.biomedcentral.com/1471-2466/9/31
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accurate diagnosis. Nevertheless, spirometry should be
used in diagnosing asthma, as the positive predictive
value has been comparatively high in general practice.
One important limitation was that 22% of the spirometric
maneuvers were not performed correctly in general prac-
tice. However, with the analysis of the spirometric maneu-
vers as part of the WBP investigation in the lung function
laboratory, we received accurate diagnostic values of
spirometry. Our results revealed that the predictive values
of general practice were slightly lower than in the lung
function laboratory. In addition to this, it was not possi-
ble to include all patients consecutively, as some patients
were not willing to travel to the lung function laboratory
of the Medical Hospital. This might have led to an overes-
timation of the diagnostic accuracy of spirometry [36].
However, that would also emphasize the impossibility of
excluding asthma solely with spirometry. Another limita-
tion is due to the choice of the cut-off points. Our use of
the ratio FEV1/VC  ≤ 0.70 as is still recommended by
GOLD [5] may have led to some overestimation of airway
obstruction in older patients [37] and underestimation in
younger patients [38]. The ATS/ERS guideline therefore
suggests using lower limits of normal, which is statistically
defined by the 5th lower percentile of a reference popula-
tion, to provide more accurate diagnoses [19]. This diag-
nostic algorithm was not integrated in the spirometric
software at the time of our study. Moreover, we are aware
of the limitations of a one-off lung function test to deter-
mine a final diagnosis, as a negative bronchodilator
response can occur due to fixed airway obstruction in
asthma. A trial of steroids might have been necessary to
differentiate between asthma and COPD in some patients.
Nevertheless, these limitations do not hamper our finding
that asthma cannot be excluded solely with spirometry.
The WBP showed little added value on top of spirometry.
We used it as a reference standard to distinguish between
overlapping diseases, COPD and restrictive lung disorder.
However, we only experienced two changes in making the
diagnosis with the added information of WBP. In two
patients suffering from dyspnea attacks, the airway resist-
ance was very high during bronchial provocation, but
FEV1 remained normal. Moreover, we found no patient
with restrictive lung disorder, which indicates a low prev-
alence in primary care settings. Therefore, the added value
of WBP for primary care is limited and it should be
reserved for patients who are difficult to diagnose and
show persistent complaints.
It was not possible to specify the alternate diagnosis of the
patients with no OAD, which is a typical problem of diag-
nostic studies in primary care. It was impossible to per-
form every investigation (e.g. gastroscopy to determine
gastro-oesophageal reflux; x-ray) until a definite diagnosis
could be made. This would not have been allowed by the
Ethics Committee. However, this limitation does not alter
the results of spirometric investigation. Finally, the partic-
ipating GPs and practice assistants were highly motivated
and received intensive training. Nevertheless, 22% of the
spirometric maneuvers showed no guideline adherence.
In particular bronchodilation testing was not performed
regularly which might be due to organisational reasons
and time constraints in general practice. The GPs esti-
mated fourteen patients to suffer from COPD. However,
the final pneumologists' diagnosis of these patients was
asthma due to positive bronchodilator testing. Therefore,
this lack of performance led the GPs to over-estimate
COPD and under-estimate asthma in patients with airway
obstruction. This is of importance as patients with asthma
need to be treated preferably with inhaled steroids. How-
ever, our results are better than demonstrated by Mirav-
itlles et al. [39], which might be due to the repeated
education of the whole practice team. Nevertheless, these
results are not satisfying enough. Further efforts are neces-
sary to improve the performance of spirometry, as this
could enhance the diagnostic accuracy. It has already been
established that GPs are able to perform and interpret
spirometry after educational meetings [40] and that per-
forming spirometry has a positive impact on medical deci-
sion making [6,30,41]. It therefore seems reasonable and
valuable to implement high quality spirometry in primary
care.
Conclusion
COPD can be estimated with high diagnostic accuracy
using spirometry. It is also possible to rule in asthma with
spirometry. However, asthma can not be ruled out only
using spirometry. This diagnostic uncertainty leads to an
overestimation of asthma presence. Patients with incon-
clusive spirometric results should be referred for NO –
measurement and/or bronchial provocation if possible to
guarantee accurate diagnosis.
Table 6: Agreement between pneumologists' and general practitioners' diagnoses
Pneumlogist\GP Asthma COPD No OAD Restrictive lung disease
n (%) n (%) n (%) n (%)
Asthma (n = 90) 69 (76.7) 14 (15.5) 7 (7.8) 0 (0)
COPD (n = 50) 7 (16.2) 41 (82.0) 1 (2.7) 1 (0)
No OAD (n = 79) 46 (58.2) 8 (10.1) 25 (31.6) 0 (0)BMC Pulmonary Medicine 2009, 9:31 http://www.biomedcentral.com/1471-2466/9/31
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